welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Prognostic Factors Affecting Duchenne Muscular Dystrophy
study id #: NCT03372655
condition: Duchenne Muscular Dystrophy
status: not yet recruitingpurpose:
Determination of prognostic factors affecting ambulation of duchenne muscular dystrophy
mechanism of action: No pharmaceutical intervention
last updated: November 22, 2018
start date: January 1, 2018
estimated completion: January 1, 2019
size / enrollment: 82
Duchenne muscular dystrophy is the most common herditary muscular disease , it lead to loss of ambulation in early teenageers . It lead to early death at the mean age of 19 years
- Ten meter walking test [Time Frame: 2018 - 2019]
- Muscle strength [Time Frame: 2018- 2019]
Any male pt diagnosed as Duchenne muscular dystrophy by typical clinical picture & shooting serum CPK level & EMG study or biopsy & age 10 to 18yrs old
Female patient' age below 10 yrs old or above 18 yrs old. Patient with autoimmune disease or malignancy.
Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Musc...This is a multi-center, randomized, doub...
A phase 2 trial of the safety and pharmacokinetics of ataluren in patients aged 2 to 5 years with nonsense mutation ...Nonsense mutation Duchenne muscular dyst...
Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrop...it is a randomised, double blind, parall...
Magnetic Resonance Imaging and Biomarkers for Muscular DystrophyThe purpose of this research study is to...
Sedation During Muscle Biopsy in Patients With Duchenne Muscular DystrophyThis is an interventional study on Duche...
Brief Overview: Duchenne Muscular Dystrophyhttps://www.slideshare.net/visprod/duche...
Extracellular RNAs in Urine May Work as Biomarker for Duchenne and Myotonic Dystrophy PatientsExtracellular RNAs found in urine may be...
Capricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical TrialCapricor Therapeutics announced today th...
Targeted re-sequencing emulsion PCR panel for myopathies: Results in 94 casesBackground: Molecular diagnostics in th...